Ocrelizumab and hyaluronidase is now the first and only twice-yearly subcutaneous injection approved for relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). The ...
"A monthly dosing schedule offers patients convenience without sacrificing efficacy," said Danny Nguyen, M.D., Assistant Clinical Professor, Department of Medical Oncology & Therapeutics Research, ...
New designation is based on data showing rapid and durable responses in a heavily pretreated patient population and expands the promise of RYBREVANT FASPRO™ beyond lung cancer RARITAN, N.J., Feb. 18, ...
SAN DIEGO, Dec. 18, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Johnson & Johnson has received approval from the U.S. Food and Drug Administration ...
Findings showed patients treated with efgartigimod alfa–hyaluronidase achieved a statistically significant improvement in MGII PRO ocular scores vs placebo at week 4. Topline data were announced from ...
The study, evaluating the efficacy of the combination of efgartigimod alfa and hyaluronidase-qvfc, is the first to ...
Ocrevus Zunovo (ocrelizumab/hyaluronidase-ocsq) is a prescription drug that’s used to treat certain forms of multiple sclerosis (MS). Ocrevus Zunovo comes as a ...
Please provide your email address to receive an email when new articles are posted on . Vascular occlusion occurs when the filler is unintentionally injected into a blood vessel, causing embolic ...
October 9, 2012 (Berlin, Germany) — In a randomized, double-blind, comparator-controlled, 2-way crossover trial, 2 rapid-acting insulin analogs (lispro or aspart) formulated with recombinant human ...
Builds on RYBREVANT FASPRO™ FDA approval to deliver the simplest and fastest combination regimen for EGFR+ non-small cell lung cancer 1,3-6 HORSHAM, Pa., Feb. 17, 2026 /PRNewswire/ -- Johnson & ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results